SA518400501B1 - مركبات [8- (فنيل سلفونيل)-3، 8-ديازا ثنائي سيكلو [3. 2. 1] أوكتـ-3-يل] ميثانون (1h-1، 2، 3-تريازول-4-يل) - Google Patents

مركبات [8- (فنيل سلفونيل)-3، 8-ديازا ثنائي سيكلو [3. 2. 1] أوكتـ-3-يل] ميثانون (1h-1، 2، 3-تريازول-4-يل)

Info

Publication number
SA518400501B1
SA518400501B1 SA518400501A SA518400501A SA518400501B1 SA 518400501 B1 SA518400501 B1 SA 518400501B1 SA 518400501 A SA518400501 A SA 518400501A SA 518400501 A SA518400501 A SA 518400501A SA 518400501 B1 SA518400501 B1 SA 518400501B1
Authority
SA
Saudi Arabia
Prior art keywords
compounds
disorders
phenylsulfonyl
triazol
diazabicyclo
Prior art date
Application number
SA518400501A
Other languages
English (en)
Inventor
روتمان أنتجي
تير لاك أنتونيوس
واجنفلد أندريا
تيريبيسي إيلديكو
بادر بنجامين
نوبيميير رينارد
كوبيتز ماركوس
بيترس مايكل
إيرلباتشر هورست
ستوبر هولغر
سيبينيتشير هولغر
Original Assignee
باير فارما أكتينجسلشافت
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by باير فارما أكتينجسلشافت filed Critical باير فارما أكتينجسلشافت
Publication of SA518400501B1 publication Critical patent/SA518400501B1/ar

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995Pyrazines or piperazines forming part of bridged ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/10Anti-acne agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/14Drugs for dermatological disorders for baldness or alopecia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

يتعلق الاختراع الحالي بـمركبات [8-(phenylsulfonyl)-3,8-diazabicyclo[3.2.1]oct-3-yl](1H-1,2,3-triazol-4-yl)methanone بالصيغة العامة (I): حيث يكون كل من R1, R2, R3, R4 و R5 كما عرف هنا، وطرق لتحضير المركبات المذكورة، ومركبات وسيطة مفيدة لتحضير المركبات المذكورة، تراكيب صيدلية وتوليفات تشمل المركبات المذكورة واستخدام المركبات المذكورة لتصنيع التراكيب الصيدلية للمعالجة أو الوقاية من اضطرابات، تحديدا اضطرابات خاصة بأمراض النساء، اضطرابات فرط التكاثر، اضطرابات أيضية، أو اضطرابات التهابية في صورة عامل منفرد أو في توليفة مع مكونات فعالة أخرى.
SA518400501A 2016-05-26 2018-11-25 مركبات [8- (فنيل سلفونيل)-3، 8-ديازا ثنائي سيكلو [3. 2. 1] أوكتـ-3-يل] ميثانون (1h-1، 2، 3-تريازول-4-يل) SA518400501B1 (ar)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16171538 2016-05-26
EP16178891 2016-07-11
PCT/EP2017/062359 WO2017202817A1 (en) 2016-05-26 2017-05-23 [8-(phenylsulfonyl)-3,8-diazabicyclo[3.2.1]oct-3-yl] (1h-1,2,3-triazol-4-yl)methanones

Publications (1)

Publication Number Publication Date
SA518400501B1 true SA518400501B1 (ar) 2022-01-16

Family

ID=58765840

Family Applications (1)

Application Number Title Priority Date Filing Date
SA518400501A SA518400501B1 (ar) 2016-05-26 2018-11-25 مركبات [8- (فنيل سلفونيل)-3، 8-ديازا ثنائي سيكلو [3. 2. 1] أوكتـ-3-يل] ميثانون (1h-1، 2، 3-تريازول-4-يل)

Country Status (25)

Country Link
US (1) US10167293B2 (ar)
EP (1) EP3464288B1 (ar)
JP (1) JP6918020B2 (ar)
KR (2) KR102373202B1 (ar)
CN (4) CN109311898B (ar)
AU (1) AU2017269871B2 (ar)
BR (1) BR112018074381B1 (ar)
CA (1) CA3025420A1 (ar)
CY (1) CY1123955T1 (ar)
DK (1) DK3464288T3 (ar)
ES (1) ES2856964T3 (ar)
HR (1) HRP20210424T1 (ar)
HU (1) HUE053438T2 (ar)
IL (1) IL262982B (ar)
LT (1) LT3464288T (ar)
MX (1) MX2018014541A (ar)
PE (1) PE20190204A1 (ar)
PL (1) PL3464288T3 (ar)
RS (1) RS61520B1 (ar)
SA (1) SA518400501B1 (ar)
SG (1) SG11201809469QA (ar)
SI (1) SI3464288T1 (ar)
TW (1) TWI738782B (ar)
UY (1) UY37262A (ar)
WO (1) WO2017202817A1 (ar)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201825478A (zh) * 2016-12-19 2018-07-16 德商拜耳製藥公司 [4-(苯基磺醯基)哌嗪-1--基](1h-1,2,3-三唑-4-基)甲酮
JP7178075B2 (ja) * 2018-03-22 2022-11-25 株式会社ユニバーサルコーポレーション Akr1c3選択的阻害剤及びその用途
CN110183455B (zh) * 2019-06-18 2021-04-20 中国医科大学 氮杂双环[3.2.1]辛-3-酮类化合物及其制备方法与其用途
WO2021000862A1 (zh) 2019-07-01 2021-01-07 深圳艾欣达伟医药科技有限公司 Akr1c3抑制剂及医药用途
UY38806A (es) * 2019-08-01 2021-02-26 Novartis Ag Compuestos inhibidores tricíclicos de kars dependientes de akr1c3, composiciones y sus usos

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1094798A2 (en) 1998-03-11 2001-05-02 Endorecherche Inc. INHIBITORS OF TYPE 5 AND TYPE 3 17beta-HYDROXYSTEROID DEHYDROGENASE AND METHODS FOR THEIR USE
CN101395134B (zh) * 2006-03-02 2011-08-31 安斯泰来制药有限公司 17β-羟类固醇脱氢酶5型抑制剂
US20070259879A1 (en) 2006-03-06 2007-11-08 Trimeris, Inc. Piperazine and piperidine biaryl derivatives
AU2007231594A1 (en) 2006-03-23 2007-10-04 Amgen Inc. 1-phenylsulfonyl-diaza heterocyclic amide compounds and their uses as modulators of hydroxsteroid dehydrogenases
RU2008145871A (ru) 2006-04-21 2010-05-27 Смитклайн Бичам Корпорейшн (US) Антагонисты рецептора il-8
MX2009000513A (es) * 2006-07-14 2009-03-09 Genelabs Tech Inc Agentes antivirales.
EP2056828A4 (en) 2006-08-21 2010-06-23 Merck Sharp & Dohme SULFONYLATED PIPERAZINES AS CANNABINOID-1 RECEPTOR MODULATORS
CN101772511A (zh) * 2007-02-16 2010-07-07 太平洋艾瑞有限公司 通过影响粘连蛋白质表达阻止癌细胞的转移和新化合物及其应用
WO2009070305A1 (en) * 2007-11-26 2009-06-04 Eisai E & D Management Co., Ltd. Method of making imidazoazepinone compounds
JP5578498B2 (ja) * 2009-11-10 2014-08-27 国立大学法人 千葉大学 抗癌剤キット及び抗癌剤効果増強剤
DE102011083725A1 (de) 2011-09-29 2013-04-04 Bayer Pharma AG Estra-1,3,5(10),16-tetraen-3-carboxamid-Derivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln
EP3078374B1 (en) 2011-10-17 2019-06-19 Vanderbilt University Indomethacin analogs for the treatment of castrate-resistant prostate cancer
WO2013142390A1 (en) 2012-03-21 2013-09-26 Gtx, Inc. Aldo-keto reductase subfamily 1c3 (akr1c3) inhibitors
PE20150353A1 (es) 2012-07-10 2015-03-28 Bayer Pharma AG Derivados de estra-1,3,5(10),16-tetraeno 3-sustituidos, metodos para su preparacion, preparaciones farmaceuticas que los contienen, asi como su uso para la preparacion de medicamentos
JP6333251B2 (ja) * 2012-08-16 2018-05-30 バイエル ファーマ アクチエンゲゼルシャフト 2,3−ベンゾジアゼピン類
WO2014039820A1 (en) 2012-09-07 2014-03-13 Gtx, Inc. Aldo-keto reductase subfamily 1c3 (akr1c3) inhibitors
AU2014220800A1 (en) * 2013-02-21 2015-08-27 Bayer Pharma Aktiengesellschaft Estra-1,3,5(10),16-tetraene-3-carboxamides for inhibition of 17.beta.-hydroxysteroid dehydrogenase (AKR1 C3)
JP2015020966A (ja) * 2013-07-18 2015-02-02 岐阜市 Akr1c3阻害剤
WO2016037956A1 (en) * 2014-09-11 2016-03-17 Bayer Pharma Aktiengesellschaft 3-nitrogen or sulphur substituted oestra-1,3,5(10),16-tetraene akr1c3 inhibitors

Also Published As

Publication number Publication date
UY37262A (es) 2018-01-02
KR20190009318A (ko) 2019-01-28
WO2017202817A9 (en) 2018-12-06
TW201742868A (zh) 2017-12-16
TWI738782B (zh) 2021-09-11
CN114702503B (zh) 2023-12-22
CN114702503A (zh) 2022-07-05
KR102373202B1 (ko) 2022-03-10
MX2018014541A (es) 2019-03-28
LT3464288T (lt) 2021-01-25
HRP20210424T1 (hr) 2021-04-30
SI3464288T1 (sl) 2021-03-31
CN114699413A (zh) 2022-07-05
IL262982A (en) 2018-12-31
SG11201809469QA (en) 2018-11-29
EP3464288B1 (en) 2020-12-23
US20180319807A2 (en) 2018-11-08
RS61520B1 (sr) 2021-03-31
HUE053438T2 (hu) 2021-06-28
CY1123955T1 (el) 2022-05-27
EP3464288A1 (en) 2019-04-10
US20170342082A1 (en) 2017-11-30
DK3464288T3 (da) 2021-03-08
KR20220035507A (ko) 2022-03-22
PL3464288T3 (pl) 2021-07-12
WO2017202817A1 (en) 2017-11-30
CN109311898B (zh) 2022-04-12
IL262982B (en) 2022-03-01
ES2856964T3 (es) 2021-09-28
BR112018074381A2 (pt) 2019-03-06
JP2019516763A (ja) 2019-06-20
CA3025420A1 (en) 2017-11-30
BR112018074381B1 (pt) 2024-01-23
PE20190204A1 (es) 2019-02-05
KR102509150B1 (ko) 2023-03-10
JP6918020B2 (ja) 2021-08-11
AU2017269871A1 (en) 2018-11-15
US10167293B2 (en) 2019-01-01
CN109311898A (zh) 2019-02-05
CN114699414A (zh) 2022-07-05
AU2017269871B2 (en) 2021-05-20

Similar Documents

Publication Publication Date Title
PH12018550173A1 (en) Pyrazolopyrimidine derivatives
PH12019500932A1 (en) 2,4,5-trisubstituted 1,2,4-triazolones useful as inhibitors of dhodh
SA518400501B1 (ar) مركبات [8- (فنيل سلفونيل)-3، 8-ديازا ثنائي سيكلو [3. 2. 1] أوكتـ-3-يل] ميثانون (1h-1، 2، 3-تريازول-4-يل)
PH12019501846A1 (en) 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer
PH12018502472A1 (en) 3-oxo-2,6-diphenyl-2,3-dihydropyridazine-4-carboxamides
WO2018077944A3 (en) 4,5-annulated 1,2,4-triazolones
PH12019501034A1 (en) New anthelmintic quinoline-3-carboxamide derivatives
PH12020500257A1 (en) Quinoline derivatives for treating infections with helminths
JO3447B1 (ar) 2-(مورفولين-4-يل)-7،1-نفثيريدينات
PH12019502851A1 (en) New azaquinoline derivatives
PH12020500134A1 (en) Dihydrooxadiazinones
MX2019012803A (es) Nuevos derivados de pirazol biciclicos.
WO2017198341A8 (en) MACROCYCLIC INDOLE DERIVATIVES
PH12020551891A1 (en) New quinoline derivatives
PH12017501133A1 (en) Pyrazolopyridinamines
WO2015150449A3 (en) Amido-substituted azole compounds as inhibitors of tnks1 and/or tnks2
MX2020004981A (es) Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3.
PH12019500808A1 (en) Substituted 6-(1h-pyrazol-1-yl)pyrimidin-4-amine derivatives and uses thereof
UY37530A (es) [4-(fenilsulfonil)piperazin-1-il](1h-1,2,3-triazol-4-il)metanonas
WO2018114677A3 (en) [(phenylsulfonyl)octahydro-epiminoisoindol-yl](1h-1,2,3-triazol-5-yl)methanones
EA201892684A1 (ru) [8-(фенилсульфонил)-3,8-диазабицикло[3.2.1]окт-3-ил](1н-1,2,3-триазол-4-ил)метаноны